Portside Wealth Group’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$666K Buy
8,505
+147
+2% +$10K 0.08% 251
2026
Q1
$540K Sell
8,358
-143
-2% -$10.1K 0.07% 244
2025
Q4
$572K Buy
8,501
+69
+0.8% +$4.64K 0.08% 229
2025
Q3
$618K Sell
8,432
-1,553
-16% -$103K 0.09% 226
2025
Q2
$519K Sell
9,985
-660
-6% -$37.6K 0.08% 236
2025
Q1
$679K Buy
10,645
+1,328
+14% +$77.1K 0.11% 196
2024
Q4
$445K Buy
9,317
+194
+2% +$9.95K 0.07% 249
2024
Q3
$522K Buy
9,123
+5,192
+132% +$298K 0.09% 219
2024
Q2
$206K Buy
+3,931
New +$172K 0.04% 340
2023
Q4
Sell
-5,601
Closed -$214K 378
2023
Q3
$214K Buy
+5,601
New +$229K 0.04% 308

Other funds holding HALO

Portside Wealth Group's HALO Position: Q2 2026 in Review

Portside Wealth Group increased its Halozyme (HALO) stake by 1.8% in Q2 2026, buying an estimated $10K and bringing the position to 8,505 shares worth $666K. The position accounts for 0.08% of the portfolio, ranked #251.

Portside Wealth Group first reported a position in HALO in Q3 2023 and has held it in 10 quarters since. The position peaked at $679K in Q1 2025. 82 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Portside Wealth Group held 8,505 shares of Halozyme worth $666K as of Q2 2026.
  • Portside Wealth Group bought 147 Halozyme shares in Q2 2026, an estimated $10K.
  • Halozyme made up 0.08% of Portside Wealth Group's portfolio in Q2 2026, its #251 holding.
  • Portside Wealth Group first reported a position in Halozyme in Q3 2023 and has held it in 10 quarters since.
  • Portside Wealth Group's Halozyme position peaked at $679K in Q1 2025.
  • 82 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Portside Wealth Group's 13F filing for Q2 2026, filed 14 Jul 2026.